Home/Pipeline/RESCAP®

RESCAP®

Prevention of complications (e.g., Acute Kidney Injury) in patients undergoing cardiothoracic surgery

Phase IIb / IIIActive, Continuation Phase Started (Oct 2024). Three-arm study (APPIRED III).

Key Facts

Indication
Prevention of complications (e.g., Acute Kidney Injury) in patients undergoing cardiothoracic surgery
Phase
Phase IIb / III
Status
Active, Continuation Phase Started (Oct 2024). Three-arm study (APPIRED III).
Company

About Alloksys Life Sciences

Alloksys Life Sciences is a private, clinical-stage biotechnology company focused on transforming critical care medicine through its proprietary enzyme therapy, RESCAP® (rescuing alkaline phosphatase). The company's mission is to develop innovative treatments that expedite patient recovery, reduce severe complications like acute kidney injury, and lower mortality in intensive care settings. With positive interim Phase IIb results and ongoing Phase IIb/III trials, Alloksys is strategically targeting high-unmet-need indications in perioperative care, aiming to bring a first-in-class therapeutic to a rapidly growing critical care market.

View full company profile

About Alloksys Life Sciences

Alloksys Life Sciences is a private, clinical-stage biotechnology company focused on transforming critical care medicine through its proprietary enzyme therapy, RESCAP® (rescuing alkaline phosphatase). The company's mission is to develop innovative treatments that expedite patient recovery, reduce severe complications like acute kidney injury, and lower mortality in intensive care settings. With positive interim Phase IIb results and ongoing Phase IIb/III trials, Alloksys is strategically targeting high-unmet-need indications in perioperative care, aiming to bring a first-in-class therapeutic to a rapidly growing critical care market.

View full company profile